Oncology

News

CHMP backs Ipsen drug for childhood brain cancer

Ipsen's Ojemda is on course to become the first targeted medicine in the EU for some children with a form of brain cancer known as low-grade glioma.

News

Hernexeos box, two pills, and pill bottle

Boehringer gets FDA's second 'national priority' approval

Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.

News

Generate's IPO gets over the line, raising $400m

AI-powered drug developer Generate Biomedicine completes a $400m IPO, the largest for biotech on the Nasdaq so far this year.

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

CHMP backs Ipsen drug for childhood brain cancer

Boehringer gets FDA's second 'national priority' approval

Generate's IPO gets over the line, raising $400m

MSD splits pharma business, hiving off oncology

FDA clears first all-oral combo for first-line CLL treatment

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Lilly plans Q1 2027 filing for obesity triple retatrutide

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks